Thursday, July 30, 2015 11:22:14 PM
GYST
Current Float Per DCT report and Q? and A
Jul 29, 2015
OTC Disclosure & News Service
Las Vegas, NV -
Some questions have been asked by shareholders of GYST and the company has decided to answer the questions in this forum as a public disclosure rather than answer the shareholders individually.
Q. Is the company still Prospecting or in production?
A. Yes, as previously disclosed we have mining claims and mining camps currently active in South America. The company has revenue from mining operations.
Q. Is the company doing a corporate buy back?
A. No, the company is not currently participating in a corporate buy back and it was never announced that the company intends to buy back shares on the open market.
It was announced that an affiliate company of the CEO has the intention of purchasing shares on the open market. That announcement is still valid and will continue through the end of this year.
Q. How many shares of the company stock has its Officers, Directors, affiliates sold since the November 3 2014 reverse?
A. None, the last sale of company stock by an officer/director/or affiliate was in 2013. This has been confirmed with the companiesTransfer Agent. (This also includes family members.)
The Company and its CEO are of the opinion that any comments to the contrary are false and/or misleading.
Q. How many shares are currently active in the float?
A. 15,248,928
Please see the attached DTC securities position report.
DTC Security position report for GYST July 2015
My comments are my opinions and observations only and should be considered as such.
Recent GYST News
- The Graystone Company Announces Completion of Acquisition of Direct Capital via Reverse Merger • InvestorsHub NewsWire • 09/11/2023 01:00:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM